Artelo Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARTL and other ETFs, options, and stocks.About ARTL
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal.
CEOGregory D. Gorgas
CEOGregory D. Gorgas
Employees6
Employees6
HeadquartersSolana Beach, California
HeadquartersSolana Beach, California
Founded2011
Founded2011
Employees6
Employees6
ARTL Key Statistics
Market cap7.53M
Market cap7.53M
Price-Earnings ratio-0.28
Price-Earnings ratio-0.28
Dividend yield—
Dividend yield—
Average volume205.05K
Average volume205.05K
High today$5.31
High today$5.31
Low today$5.31
Low today$5.31
Open price$4.85
Open price$4.85
Volume458.00
Volume458.00
52 Week high$28.60
52 Week high$28.60
52 Week low$4.20
52 Week low$4.20
ARTL News
TipRanks 5d
Artelo Biosciences announces publication of preclinical data on ART12.11Artelo Biosciences (ARTL) announced the publication of new preclinical data on ART12.11, its proprietary cannabidiol:tetramethylpyrazine cocrystal. The peer-rev...
TipRanks 5d
Artelo Biosciences Updates Bylaws on September 9, 2025Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
People also own
Based on the portfolios of people who own ARTL. This list is generated using Robinhood data, and it’s not a recommendation.